|
|
 | | | |
- close
- close
- close
- close
Orexigen Therapeutics (OREX) |
QUOTE AND NEWS
StreetInsider.com
Mar 29
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/FDA+Panel+Votes+17-6+Obesity+Drugmakers+Should+Study+Heart+Risks%3B+Watch+Orexigen+%28OREX%2C+VIVUS+%28VVUS%29%2C+Arena+%28ARNA%29/7307014.html for the full story.
Marketwire
Mar 29
Comment
NEW YORK, NY -- (Marketwire) -- 03/29/12 -- The FDA is close to approving the first weight loss drug since Roche Holding AG's Xenical in 1999. Obesity treatment manufacturers may need to study the heart risks of their medicines before U.S. regulators
StreetInsider.com
Mar 26
Comment
The following is a list of notable articles to help get you through the lunch hour:
Deere (DE) Could Rise 24% in 2012, But That's Just the Start - Barron's -> Read this!
Analysts Getting Interested in Las Vegas Sands (LVS); Shares Move Higher...
StreetInsider.com
Mar 12
Comment
UPGRADES
BofA/Merrill Lynch lifts Orexigen Therapeutics (Nasdaq: OREX) from Neutral to Buy, doubling its price target from $3.50 to $7.
Exane BNP Paribas raises Carnival Corporation (NYSE: CCL) from Underperform to Outperform.
Nomura Securities...
Benzinga
Mar 12
Comment
Analysts at Jefferies & Company upgraded Cabot Corp (NYSE: CBT) from “hold” to “buy.” CBT's shares closed at $42.03 on Friday. Cabot's PEG ratio is 1.37.
Bank of America upgraded Orexigen Therapeutics Inc (NASDAQ: OREX) from...
Benzinga
Mar 12
Comment
Bank of America raises its rating on Orexigen Therapeutics (NASDAQ: OREX) to Buy with an increased $7 price objective on long-term upside with near term-drivers.
Bank of America says, "We are upgrading OREX shares to BUY and increasing our...
PR Newswire
Mar 8
Comment
SAN DIEGO, March 8, 2012 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced financial results for the three months and year ended December 31, 2011. Three
Benzinga
Feb 23
Comment
Americans have gotten so irreversibly out of shape that the markets think we are going to need a whole lot of drugs to get a handle on ourselves. Regulators are picking up on this, as they appear ready to open up to new offerings. For the first...
StreetInsider.com
Feb 23
Comment
This report is an intraday check of some of the more notable stocks that have hit a 52-week high or low so far today.
52-Week High:
VIVUS, Inc. (Nasdaq: VVUS) high of $21.44. VIVUS ripping higher today following a positive FDA panel...
Phil’s Stock World
Feb 23
Comment
Courtesy of Benzinga. Americans have gotten so irreversibly out of shape that the markets think we are going to need a [...]
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
References
| |||||||
